Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
Hs 578T Volasertib
0.031623
PLK
Cell cycle
 -0.2839 0.59291
HME1 Dinaciclib
0.1
pan CDK
Cell cycle
 -0.2822 0.56449
SK-BR-3 Volasertib
0.31623
PLK
Cell cycle
 -0.2822 0.51136
CAL-51 Tivantinib
10.0
MET
RTK
 -0.2821 0.41896
Hs 578T Volasertib
1.0
PLK
Cell cycle
 -0.2818 0.51440
HCC70 Tivantinib
1.0
MET
RTK
 -0.2816 0.46209
CAL-51 Luminespib
0.031623
HSP90
Misc
 -0.2815 0.55665
HCC1500 Everolimus
0.01
mTOR1
PI3K/mTOR
 -0.2812 0.25609
MDA-MB-436 AZD7762
10.0
CHK1/2
Cell cycle
 -0.2809 0.26215
MDA-MB-157 Bleomycin
10.0
Radiation
Misc
 -0.2808 0.20652
HCC1419 Luminespib
0.1
HSP90
Misc
 -0.2807 0.34495
PDXHCI002 Luminespib
1.0
HSP90
Misc
 -0.2805 0.27430
PDX1328 Etoposide
10.0
Topo II
Chemotherapy
 -0.2805 0.10109
MDA-MB-453 Dinaciclib
0.1
pan CDK
Cell cycle
 -0.2799 0.31027
BT-549 Dinaciclib
0.31623
pan CDK
Cell cycle
 -0.2793 0.29019
Hs 578T Tivantinib
3.1623
MET
RTK
 -0.2792 0.56579
CAL-85-1 Taxol
1.0
Chemo
Chemotherapy
 -0.2791 0.55869
SK-BR-3 INK-128
0.1
mTORC1/2
PI3K/mTOR
 -0.2787 0.37272
CAMA-1 Vorinostat
3.1623
HDAC
Misc
 -0.2787 0.47700
MDA-MB-134-VI Ceritinib
1.0
ALK
RTK
 -0.2784 0.17358
HME1 Dinaciclib
0.31623
pan CDK
Cell cycle
 -0.2779 0.54016
Hs 578T Volasertib
0.1
PLK
Cell cycle
 -0.2776 0.57923
SK-BR-3 Doxorubicin
0.031623
Chemo
Chemotherapy
 -0.2775 0.37593
HCC1143 Taxol
0.31623
Chemo
Chemotherapy
 -0.2774 0.50922
SK-BR-3 Volasertib
0.031623
PLK
Cell cycle
 -0.2769 0.50115